The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States
- PMID: 37434347
- DOI: 10.1111/add.16291
The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States
Abstract
Aims, design and setting: We sought to describe longitudinal trends in buprenorphine receipt and buprenorphine-waivered providers in the United States from 2003 to 2021 and measure whether the relationship between the two differed after capacity-building strategies were enacted nationally in 2017. This was a retrospective study of two separate cohorts covering the years 2003-21, testing whether the association between two trends in these cohorts changed comparing 2003 to 2016 and from 2017 to 2021, among buprenorphine providers in the United States, regardless of treatment setting. Patients receiving dispensed buprenorphine at retail pharmacies.
Participants: All providers who have obtained a waiver to prescribe buprenorphine in the United States, and an estimate of the annual number of patients who had buprenorphine for opioid use disorder (OUD) dispensed to them at a retail pharmacy.
Measurements: We synthesized and summarized data from multiple sources to assess the cumulative number of buprenorphine-waivered providers over time. We used national-level prescription data from IQVIA to estimate annual buprenorphine receipt for OUD.
Findings: From 2003 to 2021, the number of buprenorphine-waivered providers in the United States increased from fewer than 5000 in the first 2 years of Food and Drug Administration (FDA) approval to more than 114 000 in 2021, while patients receiving buprenorphine products for OUD increased from approximately 19 000 to more than 1.4 million. The strength of association between waivered providers and patients is significantly different before and after 2017 (P < 0.001). From 2003 to 2016, for each additional provider, there was an average increase of 32.1 [95% confidence interval (CI) = 28.7-35.6] patients, but an increase of only 4.6 (95% CI= 3.5-5.7) patients for each additional provider, beginning in 2017.
Conclusions: In the United States, the relationship between the rates of growth in buprenorphine providers and patients became weaker after 2017. While efforts to increase buprenorphine-waivered providers were successful, there was less success in translating that into significant increases in buprenorphine receipt.
Keywords: Buprenorphine capacity; buprenorphine receipt; buprenorphine-waivered providers; longitudinal trends; medications for opioid use disorder; opioid use disorder.
© 2023 Society for the Study of Addiction.
Similar articles
-
The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.Health Serv Res. 2020 Jun;55(3):383-392. doi: 10.1111/1475-6773.13282. Epub 2020 Mar 12. Health Serv Res. 2020. PMID: 32166761 Free PMC article.
-
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.Neurotherapeutics. 2020 Jan;17(1):55-69. doi: 10.1007/s13311-019-00814-4. Neurotherapeutics. 2020. PMID: 31907876 Free PMC article. Review.
-
U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.Drug Alcohol Depend. 2019 Nov 1;204:107527. doi: 10.1016/j.drugalcdep.2019.06.029. Epub 2019 Aug 30. Drug Alcohol Depend. 2019. PMID: 31525570
-
Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.J Rural Health. 2019 Jan;35(1):108-112. doi: 10.1111/jrh.12307. Epub 2018 Jun 20. J Rural Health. 2019. PMID: 29923637
-
Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.Milbank Q. 2015 Sep;93(3):561-83. doi: 10.1111/1468-0009.12137. Milbank Q. 2015. PMID: 26350930 Free PMC article.
Cited by
-
County-level neonatal opioid withdrawal syndrome rates and real-world access to buprenorphine during pregnancy: An audit ("secret shopper") study in Missouri.Drug Alcohol Depend Rep. 2024 Feb 2;10:100218. doi: 10.1016/j.dadr.2024.100218. eCollection 2024 Mar. Drug Alcohol Depend Rep. 2024. PMID: 38380272 Free PMC article.
References
REFERENCES
-
- Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24:1868-1883.
-
- Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerdá M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786.
-
- Reuter P, Caulkins JP, Midgette G. Heroin use cannot be measured adequately with a general population survey. Addiction. 2021;116:2600-2609.
-
- Frank JW, Wakeman SE, Gordon AJ. No end to the crisis without an end to the waiver. Subst Abuse. 2018;39:263-265.
-
- Wakeman SE, Beletsky L. Beyond the X-next steps in policy reforms to address the overdose. Crisis. 2023;388:1639-1641.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical